SIL204 has been transitioned from regulatory preparation into an active Phase 2/3 clinical program for locally advanced pancreatic cancer, with trial initiation planned at Tel Aviv Sourasky Medical Center starting July 2026. The start follows clinical trial authorizations from regulators in both Israel and Germany, reducing regulatory execution risk and enabling enrollment to proceed.
SIL204 has been transitioned from regulatory preparation into an active Phase 2/3 clinical program for locally advanced pancreatic cancer, with trial initiation planned at Tel Aviv Sourasky Medical Center starting July 2026. The start follows clinical trial authorizations from regulators in both Israel and Germany, reducing regulatory execution risk and enabling enrollment to proceed.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
